Abstracts tagged "osteoporosis"

Abstract Number: 2122 • ACR Convergence 2025
Safety and Efficacy of Romosozumab in the Treatment of Patients with High-Risk Fracture Osteoporosis in Clinical Practice: Experience from a Tertiary University Hospital in Spain
Maryia Nikitsina¹, Cristina Valero², Miren Uriarte Ecenarro³, Ana M Ortiz³, María Ahijón Lana³, Irene Llorente³, Marina Dueñas-Ochoa⁴, Juan C Saez⁵, EVA GLORIA TOMERO MURIEL⁶, Esther Vicente-Rabaneda⁶, Isidoro Gonzalez-Alvaro⁷, Rosario Garcia Vicuña⁶ and Santos Castañeda⁸, ¹University Hospital La Princesa, Madrid, Madrid, Madrid, Spain, ²Hospital de la Princesa, Madrid, Spain, ³Hospital Universitario La Princesa, Madrid, Spain, ⁴Hospital La Princesa, Madrid, Spain, ⁵Hospital Universitario La Princesa, Madrid, Madrid, Spain, ⁶Hospital Universitario de la Princesa, Madrid, Spain, ⁷Department of Rheumatology, Hospital Universitario La Princesa, IIS, Madrid Spain, Madrid, Spain, ⁸Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: Romosozumab (RSZ) is a dual osteoanabolic agent that stimulates bone formation and reduces bone resorption, emerging as a promising option for treating osteoporosis (OP)…
Abstract Number: 1054 • ACR Convergence 2025
Comedication Patterns of Romosozumab Early Adopters Among Medicare Enrollees: An Unsupervised Clustering Approach
Ye Liu¹, Hongke Wu¹, Tarun Arora² and Jeffrey Curtis³, ¹University of Alabama at Birmingham, Birmingham, AL, ²FASTER, Birmingham, AL, ³Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Polypharmacy is a major concern in osteoporosis (OP) management, especially in older adults. Romosozumab (romo), approved in April 2019, is a parenteral OP medicine…
Abstract Number: 0344 • ACR Convergence 2025
Inpatient Zoledronic Acid for Glucocorticoid-Induced Osteoporosis Prevention
Gregory Challener¹, Zandra E. Walton¹, Christine M. Parsons¹, Aakash V. Patel², Alex Tinianow³, Molly E. Griffin¹, Raisa Lomanto Silva³, Avira Som¹, Laura J. Yockey⁴, WuQiang Fan⁵, Sheila L. Arvikar¹ and Marcy Bolster⁶, ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Boston, MA, ⁴MGH, Charlestown, MA, ⁵Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Boston, ⁶Massachusetts General Hospital, Concord, MA
Background/Purpose: Glucocorticoids are widely used in rheumatology and are associated with increased fracture risk. The 2022 ACR Guideline for the Prevention and Treatment of Glucocorticoid-induced…
Abstract Number: 2121 • ACR Convergence 2025
Prevention of Bone Mass Loss Associated With Aromatase Inhibitors in Breast Cancer. A Study in Real-World Clinical Practice.
Lucía Paz Liñeira¹, Beatriz Villapún Burgoa¹, Isabel Castrejón Fernández², José María álvaro-Gracia álvaro³, Teresa González Hernández¹, Sara López Tarruella¹ and Yolanda Jerez gilarranz¹, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Department of Rheumatology. Hospital General Universitario Gregorio Marañon. IiSGM. Universidad Complutense Madrid, Madrid, Spain, ³Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain. Department of Medicine, Complutense University, Madrid, Spain., Madrid, Madrid, Spain
Background/Purpose: Treatment with aromatase inhibitors (AIs) in patients with breast cancer is associated with accelerated bone mineral density (BMD) loss, leading to an increased risk…
Abstract Number: 1045 • ACR Convergence 2025
Bayesian Analysis of Factors Associated with Romosozumab Adherence Among Early Adopters in Medicare Beneficiaries
Hongke Wu¹, Ye Liu¹, Tarun Arora² and Jeffrey Curtis³, ¹University of Alabama at Birmingham, Birmingham, AL, ²FASTER, Birmingham, AL, ³Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: : Early adherence data for newly approved drugs guide clinical management, yet small cohorts hamper conventional analyses. Romosozumab (Romo), licensed April 2019 for high-risk…
Abstract Number: 0343 • ACR Convergence 2025
Impact of Janus Kinase Inhibitors on Bone Mineral Density and Microarchitecture in Rheumatoid and Psoriatic Arthritis: Insights from a Real-World Cohort
Edgar Wiebe¹, Dörte Huscher², Zhivana Boyadzhieva³, Andriko Palmowski⁴, Sandra Hermann¹, Burkhard Muche⁴, Arnd Kleyer⁵, David Simon⁶, Gerhard Krönke⁷, Paula Hoff⁸ and FRANK BUTTGEREIT⁹, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁷Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁸Endokrinologikum Berlin, Medizinisches Versorgungszentrum (MVZ) am Gendarmenmarkt, Berlin, Berlin, Germany, ⁹Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Janus kinase (JAK) inhibitors are an important treatment option for rheumatoid arthritis (RA) and psoriatic arthritis (PsA). By disrupting pro-inflammatory cytokine signaling (e.g., IL-6,…
Abstract Number: 2117 • ACR Convergence 2025
Denosumab Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis: A Multi-site Randomized Clinical Trial
Giovanni Adami¹, Kenneth Saag², Gary Cutter³, Rahima Begum³, Elizabeth Dye⁴, Phillip Foster⁵, Camilla Benini⁶, Carmela Dartizio⁶, Davide Gatti⁶ and Maria I. ("Maio") Danila⁷, ¹University of Verona, Italy, Verona, Italy, ²The University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, ⁴UAB, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of Verona, Verona, Italy, ⁷University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Prompt anti-resorptive treatment with bisphosphonates after denosumab discontinuation is generally recommended. Glucocorticoid users may not require longer term denosumab and are at greater fracture…
Abstract Number: 0452 • ACR Convergence 2025
Ten-Year Real-World Longitudinal Analysis of Bone Mineral Density in Rheumatoid Arthritis: Impact of RA and Osteoporosis Treatments
Keigo Hayashi¹, Kei Hirose², Natsuki Kubota¹, Yuya Terajima¹, Kazuya Matsumoto¹, Takato Nakadoi¹, Shoichi Nawachi¹, Yoshia Miyawaki³, Eri Katsuyama⁴, Takayuki Katsuyama¹, Haruki Watanabe¹, Mariko Narazaki¹, Yoshinori Matsumoto¹ and Jun Wada¹, ¹Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama city, Japan, ³Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan, ⁴Faculty of Health Science, Okayama University Medical School, Graduate School of Health Sciences, Boston, MA
Background/Purpose: Despite advancements in rheumatoid arthritis (RA) and osteoporosis management that have improved patient outcomes, osteoporosis continues to be a significant clinical concern in RA.…
Abstract Number: 0342 • ACR Convergence 2025
Comparison of Cortical Backscatter Ultrasound, Reference-Point Indentation and Bone Mineral Density in Discriminating Prevalent Fragility Fractures in Inflammatory Rheumatic Diseases: A Pilot Study
Edgar Wiebe¹, Benjamin Kuntz², Angela Galindo Santos³, Zhivana Boyadzhieva³, Sandra Hermann¹, Burkhard Muche², Andriko Palmowski², Gerhard Krönke⁴, Ralf Schmidmaier⁵, Kay Raum³ and FRANK BUTTGEREIT⁶, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁵Klinikum der Universität München, Medizinische Klinik und Poliklinik IV, München, Bayern, Germany, ⁶Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are at elevated risk for osteoporotic fragility fractures. Standard assessment via dual-energy X-ray absorptiometry (DXA) does…
Abstract Number: 2116 • ACR Convergence 2025
Romosozumab in Multiple Myeloma Patients at High Risk of Fracture
Giovanni Adami¹, Mariana Diz Lopes², Martina Tinelli², Angela Bonalumi², Ombretta Viapiana² and Maurizio Rossini², ¹University of Verona, Italy, Verona, Italy, ²University of Verona, Verona, Italy
Background/Purpose: Bone damage is a key feature of multiple myeloma (MM). Romosozumab (ROMO), a sclerostin inhibitor, has dual anabolic and antiresorptive properties and may offer…
Abstract Number: 0383 • ACR Convergence 2025
Hidden Risk in Low Frailty: Impact of Elixhauser Comorbidities on In-Hospital Mortality Among Osteoporosis Patients — A Nationwide Analysis
Simran Bhimani¹, Anand Reddy Maligireddy², Sameer Bhimani³, Birju Bhatt⁴ and Nevena Barjaktarovic⁵, ¹The Wright Center for graduate medical education, Scranton, PA, ²The Wright Center GME, Scarnton, PA, ³The Wright Center for GME, scranton, PA, ⁴Solara Health NJ, New Jersey, NJ, ⁵The Wright Center, GME, Scranton, PA
Background/Purpose: Osteoporosis is a common condition associated with increased morbidity, particularly in older adults. While frailty is a known predictor of adverse outcomes, the independent…
Abstract Number: 0341 • ACR Convergence 2025
Romosozumab in patients with Osteoporosis: Safety and Efficacy analysis in Clinical Practice
Daniel Ramos Castro¹, SAMUEL LEAL², ELENA GRAU GARCIA³, Pablo Muñoz-Martínez⁴, Laura Mas Sanchez⁵, Alba Maria Torrat Noves⁶, Belen Villanueva Manes⁷, Iago Alcántara Álvarez⁸, Andres perez Hurtado⁹, Miguel Simeo Vinaixa⁹ and José Andrés Román Ivorra¹⁰, ¹Hospital Universitari i Politecnic La Fe, Valencia, Spain, ²Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ³HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Hospital Universitari i Politecnic La Fe, València, Spain, ⁶Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁷Hospital La Fe, València, Spain, ⁸Hospital Universitari i Politénic La Fe, València, Spain, ⁹Rheumatology Department. HUP La Fe, Valencia, Spain, ¹⁰Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: Osteoporosis is the most common bone metabolism disorder in developed countries. It increases the risk of fragility fractures, impairing quality of life, increasing disability,…
Abstract Number: 2621 • ACR Convergence 2025
Erosive Hand Osteoarthritis Is Associated With Increased Risk of Incident Osteoporotic Fractures In Post-menopausal Women (QUALYOR Cohort)
MAXIME AUROUX¹, MERCIER-GUERY Alexandre¹, PIOT Anne², MERLE Blandine³, PRORIOL Mathilde¹, FONTANGES Elisabeth¹, DUVERT Florence¹, Eric LESPESSAILLES⁴ and CHAPURLAT Roland¹, ¹Hospices Civils de Lyon, LYON, France, ²Centre Hospitalier Lucien Hussel, VIENNE, France, ³INSERM U¹⁰³³, LYON, France, ⁴University Hospital of Orléans, Orleans, France
Background/Purpose: Erosive hand osteoarthritis (ErHOA) is a severe form of hand osteoarthritis (HOA) characterized by greater inflammation and higher burden of disease. In this more…
Abstract Number: 2111 • ACR Convergence 2025
Cost-effectiveness Analysis of Biosimilar Denosumab for the Treatment of Women with Post-menopausal Osteoporosis in the United States: A Risk Based Analysis
Edward Li¹, Rebecca McTavish², Fatemeh Mirzayeh fashami², Sarah Kane² and Marion Schauf³, ¹Sandoz Inc., West Princeton, NJ, ²EVERSANA, Burlington, ON, Canada, ³Sandoz International GmbH, Holzkirchen, Bayern, Germany
Background/Purpose: Post-menopausal osteoporosis (PMO) significantly increases the risk of fractures in women, necessitating effective treatment strategies. The introduction of biosimilar denosumab offers the opportunity to…
Abstract Number: 0384 • ACR Convergence 2025
Hip Fracture Hospitalization Trends in Osteoporotic Patients (2016–2022): National Data Insights
Simran Bhimani¹, Anand Reddy Maligireddy², Sameer Bhimani³ and Birju Bhatt⁴, ¹The Wright Center for graduate medical education, Scranton, PA, ²The Wright Center GME, Scarnton, PA, ³The Wright Center for GME, scranton, PA, ⁴Solara Health NJ, New Jersey, NJ
Background/Purpose: Hip fractures in patients with osteoporosis are a major contributor to morbidity, mortality, and healthcare costs. While classically associated with the oldest patients, emerging…

1
2
3
…
23
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].